… Grønberg, Stein Sundstrøm Data analysis and interpretation: Bjørn H. Grønberg, Roy M.
Bremnes, Stein Kaasa, Christian von Plessen, Stein Sundstrøm Manuscript writing: …

Background. Sarcopenia is a defining feature of cancer cachexia associated with physical
decline, poor quality of life and poor prognosis. Thus, maintaining muscle mass is an …

Background Cancer wasting is characterized by muscle loss and may contribute to fatigue
and poor quality of life (QoL). Our aim was to investigate associations between skeletal …

AIM OF THE STUDY: To investigate whether patients with severe comorbidity receiving
platinum-based chemotherapy for advanced non-small-cell lung cancer (NSCLC) have a shorter …

Background & aims Recent research indicates that severe muscular depletion (sarcopenia)
is frequent in cancer patients and linked to cachexia and poor survival. Our aim was to …

The majority of cancer patients with advanced disease experience weight loss, including
loss of lean body mass. Severe weight loss is characteristic for cancer cachexia, a condition …

Background Recent research suggests a significant relationship between lean body mass (LBM)
and toxicity from chemotherapeutic agents. We investigated if higher drug doses per kg …

Background: Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for
limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but …

Background Variations in lean body mass (LBM) have been suggested to explain variations
in toxicity from systemic cancer treatment. We investigated if drug doses per kilogram of LBM …

Background. Many cancer patients receive chemotherapy and radiotherapy their last 30 days
[end of life (EOL)]. The benefit is questionable and side effects are common. The aim of this …